Disease Trends and Events in Idaho
*
Christine Hahn, MD10/23/2015
Syphilis outbreak, Treasure Valley
Ebola preparations
Assessment Hospitals prepared to receive and isolate a Person under Investigation for Ebola
Virus Disease (EVD)
decision on which hospitals to designate will be made between state and local health authorities and the hospital administration
prepared to transport patients with confirmed EVD to an Ebola treatment center, informed by discussions among public health authorities and referring and accepting physicians on a case-by-case basis
should be able to provide up to 96 hours of evaluation and care until the diagnosis is either confirmed or ruled out and discharge or transfer is completed
Source: http://www.cdc.gov/vhf/ebola/healthcare-us/preparing/hospitals.html
Idaho: progress to date Dec 11, 2014– survey sent to all Idaho acute care hospitals
Sent to CEO, COO and CNO level staff, asked for the survey to be completed by December 26
12 hospitals indicated interest initially; now 7
CDC site visit August 3-5
CDC Team
Results and Next Steps
Visits were very productive and well received
Both hospitals are considered assessment hospitals for planning purposes, although a few gaps remain (eg, laboratory protocols)
Additional hospitals are being contacted to determine interest in visit by Idaho team
Tularemia gram negative coccobacillus, Francisella tularensis, causes infection naturally found in animals, especially rodents, rabbits, and hares transmitted by multiple routes to humans:
– tick bite– deer fly bite (“deer fly fever”)– skinning infected rabbits (“rabbit fever”), muskrats, prairie dogs and other rodents– handling sick cats, pet hamster– eating under-cooked meat of infected animals– inhaling dust or aerosols during farming or landscaping activities, especially when
machinery (e.g. tractors or mowers) runs over infected animals or carcasses– drinking contaminated water (rare in US)
risk to laboratorians
Idaho tularemia 2015
9/2015, Valley County: – 77-yr old male– Patient reported possible yellow jacket sting on lower leg
but did not see it– MRSA suspected in leg ulcer– 3 laboratorians received prophylaxis
10/17/2015, Twin Falls County: – 79-yr old male– Finger wound that appeared infected– Patient reported gardening, possible puncture by thorn
Tularemia … a long recognized hazard to laboratorians
Source: Public Health Reports, Feb 24, 1922
Tularemia exposure to laboratorians
Lab personnel should be informed if tularemia is suspected clinically
BSL-2 practices recommended for handling clinical materials BSL-3 practices recommended for manipulations of positive
cultures Francisella tularensis is a Select Agent; notify public health of
suspected isolations even before confirmed if possible
Highly Pathogenic Avian Influenza outbreaks in the United States
Designation of highly pathogenic avian influenza (HPAI) is based on molecular characteristics of the virus and the ability of the virus to cause disease and mortality in chickens in a laboratory setting.
Between 1997 and 2014, the U.S. experienced one incident of HPAI in poultry.– 2004: H5N2 in Texas
• An outbreak of HPAI (H5N2) virus was reported in a flock of 7,000 chickens in south-central Texas.
• At that time, this was the first outbreak of HPAI in the United States in 20 years.
• No transmission to humans was reported.
Highly Pathogenic Avian Influenza (HPAI) 2015
Idaho Summer Preparedness Summit 2015
Kris Carter, DVM, MPVMCareer Epidemiology Field Officer
IDHW DPH
Initial noticeMay 19: Idaho Dept. of Fish and Game (IDFG) wildlife veterinarian informs IDHW DPH State Public Health Veterinarian about several ground squirrel mortality events
– earliest report May 12– several locations in Snake
River Birds of Prey National Conservation Area south of Boise
– IDFG sent specimens to CDC for testing for plague
Source: EID 2015: Jan; 21 (1): 16-22
Epidemiology of Plague in Western US: 1970-2009
Source: USGS Circular 1372
Confirmation
• May 20 — CDC reports carcasses are presumptive positive for Yersinia pestis by direct fluorescent antibody (DFA) test on tissue
• May 22 — CDC confirmed Yersinia pestis by bacterial culture
Source: CDC Public Health Image Library
Informing the Public: Posting
Informing the Public: Websites
Vaccine news 2015
HPV news 2015
Idaho and U.S.-- HPV
HPV – dose reduction coming?
33
Influenza Vaccine Recommendations, 2015-2016
Influenza Vaccine Recommendations, 2015-2016
• Routine annual influenza vaccination is recommended for all persons age 6 months and older who do not have a contraindication
• Special effort should be made to vaccinate- infants and young children and their
contacts- persons age 65 years and older and their
contacts- persons with underlying medical
conditions (including pregnancy) and their contacts
- healthcare providers
• Routine annual influenza vaccination is recommended for all persons age 6 months and older who do not have a contraindication
• Special effort should be made to vaccinate- infants and young children and their
contacts- persons age 65 years and older and their
contacts- persons with underlying medical
conditions (including pregnancy) and their contacts
- healthcare providers
MMWR 2015;64:818-25
34
What’s New for Influenza 2015-2016What’s New for Influenza 2015-2016
• H3N2 and B virus strains changed
• New vaccines (Flublok age now 18+ years, Fluzone Intradermal now quadrivalent)
• Removal of preference for LAIV for children 2 through 8 years of age
• H3N2 and B virus strains changed
• New vaccines (Flublok age now 18+ years, Fluzone Intradermal now quadrivalent)
• Removal of preference for LAIV for children 2 through 8 years of age
MMWR 2015;64:818-25
35
Fluzone High-DoseFluzone High-Dose
• Available since December 2009• Trivalent formulation only• Contains 4 X amount of influenza
antigen than regular Fluzone• Approved only for persons 65 years
and older• Produces higher antibody levels• Local reactions more frequent than
with standard dose vaccine
• Available since December 2009• Trivalent formulation only• Contains 4 X amount of influenza
antigen than regular Fluzone• Approved only for persons 65 years
and older• Produces higher antibody levels• Local reactions more frequent than
with standard dose vaccine
MMWR 2011;60:1128-32
36
Fluzone High Dose Clinical TrialFluzone High Dose Clinical Trial
• Multi-center randomized clinical trial
• 32,000 persons 65 years or older
• Compared to standard Fluzone- 24.2% reduction in laboratory-
confirmed influenza- effective against both influenza A
and B- reduction in risk of pneumonia and
hospitalization
• Multi-center randomized clinical trial
• 32,000 persons 65 years or older
• Compared to standard Fluzone- 24.2% reduction in laboratory-
confirmed influenza- effective against both influenza A
and B- reduction in risk of pneumonia and
hospitalization
N Engl J Med 2014;371:635-45
37
Adult Immunization Coverage Rates 2010 - 2013 Adult Immunization Coverage Rates 2010 - 2013
Zoster, age ≥60
Pneumococcal, age 19-64 at high risk
Pneumococcal, age ≥65
Tetanus past 10y, age 19-64
Tetanus past 10y, age ≥65
0 10 20 30 40 50 60 70 80 90 100
2013201220112010
Source: National Health Interview Surveys : Healthy People 2020 target
38
Pneumococcal Conjugate Vaccine (PCV13) and Adults
Pneumococcal Conjugate Vaccine (PCV13) and Adults
• FDA approved PCV13 for use among adults 50 years of age and older in December 2011
• Immunogenicity of PCV13 was found to be non-inferior to PPSV23
• ACIP recommended 1 dose of PCV13 for adults at high risk of invasive pneumococcal disease* in October 2012
• FDA approved PCV13 for use among adults 50 years of age and older in December 2011
• Immunogenicity of PCV13 was found to be non-inferior to PPSV23
• ACIP recommended 1 dose of PCV13 for adults at high risk of invasive pneumococcal disease* in October 2012
*immunocompromised, functional or anatomic asplenia, cochlear implant, CSF leak
39
Pneumococcal Vaccines for Persons Age 65 Years and Older
Pneumococcal Vaccines for Persons Age 65 Years and Older
• One lifetime dose of PCV13 for adults
• PCV13 and PPSV23 should NOT be administered at the same visit
• Administer PCV13 before PPSV23, whenever possible
• PCV13 should be administered to those who have already received PPSV23
• One lifetime dose of PCV13 for adults
• PCV13 and PPSV23 should NOT be administered at the same visit
• Administer PCV13 before PPSV23, whenever possible
• PCV13 should be administered to those who have already received PPSV23
MMWR 2014;63(No. 37):822-5
Pneumococcal vaccination for seniors
Source: http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6434a4.htm
4242
Meningococcal Incidence in Adolescents and Young Adults by Serogroup, 2009–2013
Meningococcal Incidence in Adolescents and Young Adults by Serogroup, 2009–2013
11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 260.0
0.1
0.2
0.3Serogroup B Serogroups C & Y
Age (years)
Inci
den
ce p
er 1
00,0
00
Source: NNDSS data supplemented with additional serogroup data from ABCs and state health departmentsSource: NNDSS data supplemented with additional serogroup data from ABCs and state health departments
43
Groups at Increased Risk for Meningococcal B Disease
Groups at Increased Risk for Meningococcal B Disease
• High-risk medical conditions: - persistent complement component
deficiencies- functional or anatomic asplenia
• Certain microbiologists
• Populations at risk during an outbreak
• NOT at increased risk: international travelers, first year college students
• High-risk medical conditions: - persistent complement component
deficiencies- functional or anatomic asplenia
• Certain microbiologists
• Populations at risk during an outbreak
• NOT at increased risk: international travelers, first year college students
CDC unpublished data
44
ACIP Recommendations for Meningococcal B Vaccine of High Risk Persons
ACIP Recommendations for Meningococcal B Vaccine of High Risk Persons
• Certain persons 10 years of age or older* who are at increased risk for meningococcal disease should receive MenB vaccine
- persistent complement component deficiency
- anatomic or functional asplenia
- risk in a serogroup B meningococcal disease outbreak
- certain microbiologists
• MenB vaccines are included in VFC
• NOT routinely recommended for college students or international travelers
• Certain persons 10 years of age or older* who are at increased risk for meningococcal disease should receive MenB vaccine
- persistent complement component deficiency
- anatomic or functional asplenia
- risk in a serogroup B meningococcal disease outbreak
- certain microbiologists
• MenB vaccines are included in VFC
• NOT routinely recommended for college students or international travelers
*off-label for persons 26 years and older. MMWR 2015;64:608-12
“A MenB vaccine series may be administered to adolescents and young adults aged 16–23 years to provide short-term protection against most strains of serogroup B meningococcal disease. The preferred age for MenB vaccination is 16–18 years.”
Bexsero® (MenB-4C, 2 doses) and Trumenba® (MenB-FHbp, 3 doses) are both licensed. The two MenB vaccines are not interchangeable; the same vaccine product must be used for all doses.
MenB-FHbp or MenB-4C may be administered concomitantly with other vaccines indicated for this age, but at a different anatomic site, if feasible.
7698 participants received the vaccine; 7713 participants got placebo Mean follow-up of 3.2 years Herpes zoster in 6 participants in the vaccine group; 210 participants in the
placebo group Overall vaccine efficacy against herpes zoster was 97.2% (95% confidence
interval [CI], 93.7 to 99.0; P<0.001).
Source: http://www.nejm.org/doi/full/10.1056/NEJMoa1501184
News from ACIP this week Influenza activity very low right now; over the summer, H3N2 predominated
Supply: 171-179 million doses of flu vaccine expected to be available; last 147.8 million were distributed. So far, 109.4 million have been distributed, similarly to last year.
Fluzone and FluZone High Dose distribution complete, other than prefilled syringes but expected to be complete by November
FluMist distribution ongoing but delayed
News from ACIP this week Early data showing impact of HPV vaccination
Early results of CDC Ebola vaccine trial
This week Investigations by local public health district epidemiologists at PHD3
and PHD4 of 4 campylobacter cases and 4 STEC cases, including two hospitalized patients
Raw milk consumption linked to illnesses
Thank You!
Top Related